AP3170A - New CCR2 receptor antagonists and uses thereof - Google Patents

New CCR2 receptor antagonists and uses thereof

Info

Publication number: AP3170A
Authority: AP; ARIPO
Prior art keywords: receptor antagonists; ccr2 receptor; new ccr2; new; antagonists
Prior art date: 2009-12-17

Application number

AP2012006276A

Other languages

English (en)

Other versions

AP2012006276A0 (en

Inventor

Kai Gerlach

Marco Santagostino

Christoph Hoenke

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-17

Filing date

2010-12-13

Publication date

2015-03-31

2010-12-13 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2012-06-30 Publication of AP2012006276A0 publication Critical patent/AP2012006276A0/xx

2015-03-31 Application granted granted Critical

2015-03-31 Publication of AP3170A publication Critical patent/AP3170A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

AP2012006276A 2009-12-17 2010-12-13 New CCR2 receptor antagonists and uses thereof AP3170A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09179555		2009-12-17
EP10162621		2010-05-12
PCT/EP2010/069549 WO2011073154A1 (en)	2009-12-17	2010-12-13	New ccr2 receptor antagonists and uses thereof

Publications (2)

Publication Number	Publication Date
AP2012006276A0 AP2012006276A0 (en)	2012-06-30
AP3170A true AP3170A (en)	2015-03-31

Family

ID=43533115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2012006276A AP3170A (en)	2009-12-17	2010-12-13	New CCR2 receptor antagonists and uses thereof

Country Status (36)

Country	Link
US (6)	US8765949B2 (xx)
EP (3)	EP2513093B1 (xx)
JP (1)	JP5632014B2 (xx)
KR (1)	KR101530234B1 (xx)
CN (1)	CN102933579B (xx)
AP (1)	AP3170A (xx)
AR (1)	AR079636A1 (xx)
AU (1)	AU2010332969B2 (xx)
BR (1)	BR112012015873B1 (xx)
CA (1)	CA2782464C (xx)
CL (1)	CL2012001311A1 (xx)
CO (1)	CO6650336A2 (xx)
CY (1)	CY1115873T1 (xx)
DK (1)	DK2513093T3 (xx)
EA (1)	EA024397B1 (xx)
EC (1)	ECSP12012010A (xx)
ES (2)	ES2524829T3 (xx)
GE (1)	GEP20146124B (xx)
HR (1)	HRP20141143T1 (xx)
IL (1)	IL219421A (xx)
MA (1)	MA33818B1 (xx)
ME (1)	ME01908B (xx)
MX (2)	MX346393B (xx)
MY (1)	MY160471A (xx)
NZ (1)	NZ599770A (xx)
PE (1)	PE20121614A1 (xx)
PH (1)	PH12012501215A1 (xx)
PL (2)	PL2513093T3 (xx)
PT (2)	PT3091012T (xx)
RS (1)	RS53555B1 (xx)
SG (1)	SG181722A1 (xx)
SI (1)	SI2513093T1 (xx)
TN (1)	TN2012000300A1 (xx)
TW (1)	TWI473800B (xx)
UY (1)	UY33109A (xx)
WO (1)	WO2011073154A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5603770B2 (ja)	2007-05-31	2014-10-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｃｒ２受容体拮抗薬およびその使用
US20120053164A1 (en) *	2008-12-19	2012-03-01	Boehringer Ingelheim International Gmbh	Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
EP2513093B1 (en)	2009-12-17	2014-08-27	Boehringer Ingelheim International GmbH	New ccr2 receptor antagonists and uses thereof
US8946218B2 (en)	2010-05-12	2015-02-03	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en)	2010-05-12	2011-11-17	Boehringer Ingelheim International Gmbh	Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en)	2010-05-17	2015-01-21	Boehringer Ingelheim International GmbH	Ccr2 antagonists and uses thereof
US9018212B2 (en)	2010-05-25	2015-04-28	Boehringer Ingelheim International Gmbh	Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en)	2010-06-01	2015-10-28	Boehringer Ingelheim International GmbH	New CCR2 antagonists
JP5786257B2 (ja) *	2011-06-16	2015-09-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規の選択的ｃｃｒ２拮抗薬
EP2731941B1 (en)	2011-07-15	2019-05-08	Boehringer Ingelheim International GmbH	Novel and selective ccr2 antagonists
EP2771484A1 (en)	2011-10-28	2014-09-03	Galderma Research & Development	New leukocyte infiltrate markers for rosacea and uses thereof
US8877185B2 (en)	2012-05-10	2014-11-04	Stan S. Sastry	Managing and treating keloids
WO2016081801A1 (en) *	2014-11-21	2016-05-26	Millennium Pharmaceuticals, Inc.	Use of an anti-ccr2 antagonist in the treatment of an infectious disease
MA42133A (fr)	2015-05-21	2021-06-02	Chemocentryx Inc	Modulateurs du ccr2
WO2017004537A1 (en) *	2015-07-02	2017-01-05	Centrexion Therapeutics Corporation	(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
WO2017210526A1 (en) *	2016-06-03	2017-12-07	Chemocentryx, Inc.	Method of treating liver fibrosis
US10195188B2 (en)	2016-06-13	2019-02-05	Chemocentryx, Inc.	Method of treating pancreatic cancer
MX382778B (es) *	2016-06-13	2025-03-13	Chemocentryx Inc	Metodos para tratar cancer pancreatico
CN108017599B (zh) *	2016-11-04	2020-03-03	上海爱科百发生物医药技术有限公司	[3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
MX388165B (es)	2016-11-23	2025-03-19	Chemocentryx Inc	Método para tratar glomeruloesclerosis segmentaria focal
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
BR112020005284A2 (pt)	2017-09-25	2020-09-24	Chemocentryx, Inc.	terapia de combinação usando um antagonista do receptor de quimiocina 2 (ccr2) e um inibidor de pd-1/pd-l1
MX386699B (es)	2017-10-11	2025-03-19	Chemocentryx Inc	Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
US20190269664A1 (en)	2018-01-08	2019-09-05	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
IL275898B2 (en)	2018-01-08	2025-05-01	Chemocentryx Inc	Methods for treating solid tumors with CCR2 antagonists
US20210322412A1 (en) *	2020-04-20	2021-10-21	Centrexion Therapeutics Corporation	Methods and compositions for treating a coronavirus infection
NL2026714B1 (en) *	2020-10-20	2022-06-16	Lumicks Ca Holding B V	Improved detection of lymphocyte - target cell interaction

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US568885A (en) *		1896-10-06		Can-seaming mechanism
US213428A (en) *		1879-03-18		Improvement in harrow-teeth
US4032526A (en)	1975-10-02	1977-06-28	American Cyanamid Company	1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
GB2068961B (en)	1980-02-13	1983-11-30	Sankyo Co	Quinazoline derivatives
DE3517617A1 (de)	1985-05-15	1986-11-20	Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München	Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
JPS6319745Y2 (xx)	1985-11-07	1988-06-01
JPS61165445A (ja)	1986-01-08	1986-07-26	株式会社巴組鐵工所	振動を減少しうる床構造
US5096916A (en)	1990-05-07	1992-03-17	Aegis Technology, Inc.	Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
DE69325662T2 (de)	1992-10-23	2000-02-10	Merck Sharp & Dohme Ltd., Hoddesdon	Dopamin rezeptor subtyp liganden
JP3166376B2 (ja)	1993-02-03	2001-05-14	松下電器産業株式会社	熱利用装置
US5629235A (en)	1995-07-05	1997-05-13	Winbond Electronics Corporation	Method for forming damage-free buried contact
TW531537B (en)	1995-12-27	2003-05-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5629325A (en)	1996-06-06	1997-05-13	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en)	1996-06-06	2002-08-20	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6979686B1 (en)	2001-12-07	2005-12-27	Pharmacia Corporation	Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
EE04588B1 (et)	1997-10-27	2006-02-15	Neurosearch A/S	Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
IL142999A0 (en)	1998-11-20	2002-04-21	Searle & Co	Process for making 5-substituted pyrazoles using dithietanes
US6248755B1 (en)	1999-04-06	2001-06-19	Merck & Co., Inc.	Pyrrolidine modulators of chemokine receptor activity
WO2000066558A1 (en)	1999-05-04	2000-11-09	Schering Corporation	Piperazine derivatives useful as ccr5 antagonists
GB0004153D0 (en)	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel use
US20020045613A1 (en)	2000-04-27	2002-04-18	Heinz Pauls	1-aroyl-piperidinyl benzamidines
AU2001257413B2 (en)	2000-05-22	2007-01-18	Aventisub Llc	Arylmethylamine derivatives for use as tryptase inhibitors
EP1326862B1 (de)	2000-10-12	2004-09-15	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG	Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
AR035700A1 (es)	2001-05-08	2004-06-23	Astrazeneca Ab	Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
IL159238A0 (en)	2001-06-22	2004-06-01	Boehringer Ingelheim Pharma	Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
WO2003037271A2 (en)	2001-10-30	2003-05-08	Millennium Pharmaceuticals,Inc.	Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en)	2001-12-17	2004-10-19	Sunesis Pharmaceuticals, Inc.	Small-molecule inhibitors of interleukin-2
IL162859A0 (en)	2002-02-05	2005-11-20	Novo Nordisk As	Novel aryl-and heteroarylpiperazines
JP2003240776A (ja)	2002-02-13	2003-08-27	Horiba Ltd	クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置
HUP0200849A2 (hu)	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20030195192A1 (en)	2002-04-05	2003-10-16	Fortuna Haviv	Nicotinamides having antiangiogenic activity
KR20040090978A (ko)	2002-03-13	2004-10-27	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
US20040014744A1 (en)	2002-04-05	2004-01-22	Fortuna Haviv	Substituted pyridines having antiangiogenic activity
WO2003090748A1 (fr)	2002-04-24	2003-11-06	Takeda Pharmaceutical Compay Limited.	Utilisation de composes a antagonisme anti-ccr
EP1501507B1 (en)	2002-04-29	2008-05-28	Merck & Co., Inc.	Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
EP1511743A1 (en)	2002-06-05	2005-03-09	Pharmacia Corporation	Pyrazole-derivatives as p38 kinase inhibitors
WO2004024710A1 (en)	2002-09-13	2004-03-25	Glaxo Group Limited	Urea compounds active as vanilloid receptor antagonists for the treatment of pain
SE0203304D0 (sv)	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Coumpounds
GB0229618D0 (en)	2002-12-19	2003-01-22	Cancer Rec Tech Ltd	Pyrazole compounds
US20040147561A1 (en)	2002-12-27	2004-07-29	Wenge Zhong	Pyrid-2-one derivatives and methods of use
WO2004074438A2 (en) *	2003-02-14	2004-09-02	Smithkline Beecham Corporation	Ccr8 antagonists
GB2415430B (en)	2003-03-12	2006-07-12	Kudos Pharm Ltd	Phthalazinone derivatives
CA2523431A1 (en)	2003-04-23	2004-11-25	Glaxo Group Limited	Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
FR2854158B1 (fr)	2003-04-25	2006-11-17	Sanofi Synthelabo	Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
US20060247227A1 (en)	2003-07-18	2006-11-02	Bailey James M	Substituted piperidines as histamine h3 receptor ligands
KR20060054392A (ko)	2003-07-29	2006-05-22	노보 노르디스크 에이/에스	피리다지닐-피페라진 및 히스타민 ｈ３ 수용체 리간드로서그들의 사용
EP1696919B1 (en)	2003-12-18	2013-10-02	Incyte Corporation	3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
GB0403155D0 (en)	2004-02-12	2004-03-17	Vernalis Res Ltd	Chemical compounds
JP4845873B2 (ja)	2004-03-03	2011-12-28	ケモセントリックスインコーポレーティッド	二環式および架橋した窒素複素環
PE20060285A1 (es)	2004-03-30	2006-05-08	Aventis Pharma Inc	Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CA2561791A1 (en)	2004-03-31	2005-10-20	Janssen Pharmaceutica, N.V.	Non-imidazole heterocyclic compounds
EP1750727A2 (en)	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
US20100234409A1 (en)	2004-05-21	2010-09-16	Lihu Yang	Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
US7507740B2 (en)	2004-06-02	2009-03-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
FR2871157A1 (fr)	2004-06-04	2005-12-09	Aventis Pharma Sa	Produits biaryl aromatiques, compositions les contenant et utilisation
WO2006012226A2 (en)	2004-06-24	2006-02-02	Incyte Corporation	N-substituted piperidines and their use as pharmaceuticals
NZ552173A (en)	2004-06-25	2010-07-30	Janssen Pharmaceutica Nv	Quaternary salt CCR2 antagonists
CN1976702A (zh) *	2004-06-28	2007-06-06	因赛特公司	作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
KR100856155B1 (ko) *	2004-06-28	2008-09-03	인사이트 코포레이션	케모카인 수용체의 조절자로서의3-아미노사이클로펜탄카복스아마이드
KR20070057859A (ko)	2004-08-26	2007-06-07	쿠도스 파마슈티칼스 리미티드	4-헤테로아릴메틸 치환된 프탈라지논 유도체
GB0420831D0 (en)	2004-09-17	2004-10-20	Glaxo Group Ltd	Novel compounds
US7767677B2 (en)	2004-09-20	2010-08-03	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
WO2006038734A1 (en)	2004-10-08	2006-04-13	Astellas Pharma Inc.	Pyridazinone derivatives cytokines inhibitors
MX2007005247A (es)	2004-11-02	2008-03-13	Univ Northwestern	Compuestos de piridazina, composiciones y metodos.
PA8653301A1 (es)	2004-11-22	2006-11-09	Incyte Corp Incyte Corp	Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
DE102004061751A1 (de)	2004-12-22	2006-07-06	Bayer Healthcare Ag	Cyanoguanidin-substituierte Pyrazoline
AU2006215080B2 (en)	2005-02-17	2011-03-10	Astellas Pharma Inc.	Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
EP2527337A1 (en)	2005-04-14	2012-11-28	Bristol-Myers Squibb Company	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2006113140A2 (en)	2005-04-15	2006-10-26	Elan Pharmaceuticals, Inc.	Novel compounds useful for bradykinin b1 receptor antagonism
TW200716594A (en)	2005-04-18	2007-05-01	Neurogen Corp	Substituted heteroaryl CB1 antagonists
WO2006127587A1 (en)	2005-05-20	2006-11-30	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
CN103110635A (zh)	2005-07-04	2013-05-22	海波因特制药有限责任公司	组胺h3受体拮抗剂
US7851474B2 (en)	2005-08-02	2010-12-14	Neurogen Corporation	Dipiperazinyl ketones and related analogues
GB0517184D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
AR055203A1 (es)	2005-08-31	2007-08-08	Otsuka Pharma Co Ltd	Derivados de benzotiofeno con propiedades antipsicoticas
TW200800999A (en)	2005-09-06	2008-01-01	Astrazeneca Ab	Novel compounds
CA2622494A1 (en)	2005-09-27	2007-04-05	Irm Llc	Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
JO2769B1 (en)	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007053498A1 (en)	2005-11-01	2007-05-10	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of ccr2
WO2007053495A2 (en)	2005-11-01	2007-05-10	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of ccr2
AU2006337682A1 (en)	2005-11-14	2007-08-16	Irm Llc	Compounds and compositions as LXR modulators
US20090182140A1 (en) *	2005-12-02	2009-07-16	Mitsubishi Tanabe Pharma Corporation	Alicyclic Heterocyclic Compound
AR058554A1 (es)	2005-12-20	2008-02-13	Novartis Ag	Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
IL172838A (en)	2005-12-27	2010-06-16	Joma Int As	Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby
WO2007084868A2 (en)	2006-01-17	2007-07-26	Kalypsys, Inc.	Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
EP2465850B1 (en)	2006-02-28	2016-11-23	Dart Neuroscience (Cayman) Ltd	Therapeutic compounds
EP2024353A2 (en)	2006-03-16	2009-02-18	Pfizer Products Inc.	Pyrazole compounds
AU2007238878A1 (en)	2006-04-11	2007-10-25	Merck Sharp & Dohme Corp.	Diaryl substituted alkanes
US7807671B2 (en)	2006-04-25	2010-10-05	Bristol-Myers Squibb Company	Diketo-piperazine and piperidine derivatives as antiviral agents
WO2007127448A2 (en)	2006-04-28	2007-11-08	Northwestern University	Salts of pyridazine compounds
EP2044051B1 (en)	2006-06-22	2010-01-27	BIOVITRUM AB (publ)	Pyridine and pyrazine derivatives as mnk kinase inhibitors
US7935715B2 (en)	2006-07-28	2011-05-03	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
GB0617575D0 (en)	2006-09-06	2006-10-18	Syngenta Ltd	Herbicidal compounds and compositions
MX2009002888A (es)	2006-09-25	2009-03-31	Boehringer Ingelheim Int	Compuestos que modulan el receptor cb2.
MX2009005252A (es)	2006-11-17	2009-05-28	Abbott Lab	Aminopirrolidinas como antagonistas del receptor de quimiocina.
PL2698062T3 (pl)	2006-12-28	2015-12-31	Abbvie Inc	Inhibitory polimerazy poli(adp-rybozy)
CA2676715A1 (en)	2007-02-12	2008-08-21	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (ja)	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
FR2915552B1 (fr)	2007-04-27	2009-11-06	Technip France	Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux.
JP5603770B2 (ja)	2007-05-31	2014-10-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｃｒ２受容体拮抗薬およびその使用
BRPI0814403A2 (pt)	2007-07-02	2015-01-27	Hoffmann La Roche	Devirados de imidazol como antagonistas de receptor ccr2
US7977358B2 (en)	2007-07-26	2011-07-12	Hoffmann-La Roche Inc.	Pyrazol derivatives
WO2009026204A1 (en)	2007-08-22	2009-02-26	Irm Llc	2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
BRPI0817935A2 (pt)	2007-10-01	2015-04-07	Hoffmann La Roche	Derivados de biarila
EP2325180A1 (en)	2007-10-09	2011-05-25	F. Hoffmann-La Roche AG	Chiral CIS-imidazolines
EP2200470A4 (en)	2007-10-12	2013-11-20	Jong O Whang	SNAIL INSTRUMENT FOR SHOES
EP2220045A1 (en)	2007-11-20	2010-08-25	Janssen Pharmaceutica, N.V.	Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2009066084A1 (en)	2007-11-21	2009-05-28	F. Hoffmann-La Roche Ag	2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
EP2225223B1 (de)	2007-11-22	2017-01-11	Boehringer Ingelheim International GmbH	Organische verbindungen
EP2062889A1 (de)	2007-11-22	2009-05-27	Boehringer Ingelheim Pharma GmbH & Co. KG	Verbindungen
CA2725657A1 (en)	2008-06-18	2009-12-23	F. Hoffmann-La Roche Ag	Novel heteroaryl carboxamide derivatives
AU2009279787B2 (en)	2008-08-04	2014-05-29	Chdi Foundation, Inc.	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB0815369D0 (en)	2008-08-22	2008-10-01	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
PE20110398A1 (es)	2008-09-02	2011-07-13	Boehringer Ingelheim Int	BENZAMIDAS CON ACTIVIDAD SOBRE LA ENZIMA p38 MAP-QUINASA
PE20110397A1 (es)	2008-09-25	2011-07-01	Boehringer Ingelheim Int	Compuestos que modulan selectivamente el receptor cb2
US20120053164A1 (en) *	2008-12-19	2012-03-01	Boehringer Ingelheim International Gmbh	Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
JP2012518603A (ja)	2009-02-23	2012-08-16	メルクカナダインコーポレイテッド	ステアロイル−コエンザイムａデルタ−９デサチュラーゼの阻害剤としての複素環誘導体
EP2513093B1 (en)	2009-12-17	2014-08-27	Boehringer Ingelheim International GmbH	New ccr2 receptor antagonists and uses thereof
EP2513086B1 (en)	2009-12-17	2015-04-29	Boehringer Ingelheim International GmbH	Novel antagonists for ccr2 and uses thereof
US8329735B2 (en)	2010-03-05	2012-12-11	Boehringer Ingelheim International Gmbh	Tetrazole compounds which selectively modulate the CB2 receptor
US8946218B2 (en)	2010-05-12	2015-02-03	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en)	2010-05-12	2011-11-17	Boehringer Ingelheim International Gmbh	Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en)	2010-05-17	2015-01-21	Boehringer Ingelheim International GmbH	Ccr2 antagonists and uses thereof
US9018212B2 (en)	2010-05-25	2015-04-28	Boehringer Ingelheim International Gmbh	Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en)	2010-06-01	2015-10-28	Boehringer Ingelheim International GmbH	New CCR2 antagonists
JP5786257B2 (ja)	2011-06-16	2015-09-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規の選択的ｃｃｒ２拮抗薬
EP2731941B1 (en)	2011-07-15	2019-05-08	Boehringer Ingelheim International GmbH	Novel and selective ccr2 antagonists
JP6229575B2 (ja)	2014-03-31	2017-11-15	京セラドキュメントソリューションズ株式会社	画像処理装置
WO2017004537A1 (en) *	2015-07-02	2017-01-05	Centrexion Therapeutics Corporation	(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate

2010
- 2010-12-13 EP EP10796336.5A patent/EP2513093B1/en active Active
- 2010-12-13 NZ NZ599770A patent/NZ599770A/en not_active IP Right Cessation
- 2010-12-13 ME MEP-2014-106A patent/ME01908B/me unknown
- 2010-12-13 EA EA201200876A patent/EA024397B1/ru not_active IP Right Cessation
- 2010-12-13 MX MX2013008863A patent/MX346393B/es unknown
- 2010-12-13 PH PH1/2012/501215A patent/PH12012501215A1/en unknown
- 2010-12-13 PE PE2012000827A patent/PE20121614A1/es active IP Right Grant
- 2010-12-13 PT PT161570270T patent/PT3091012T/pt unknown
- 2010-12-13 GE GEAP201012789A patent/GEP20146124B/en unknown
- 2010-12-13 ES ES10796336.5T patent/ES2524829T3/es active Active
- 2010-12-13 JP JP2012543667A patent/JP5632014B2/ja active Active
- 2010-12-13 CN CN201080057415.2A patent/CN102933579B/zh active Active
- 2010-12-13 EP EP14177921.5A patent/EP2813503B1/en not_active Not-in-force
- 2010-12-13 BR BR112012015873-2A patent/BR112012015873B1/pt not_active IP Right Cessation
- 2010-12-13 PT PT107963365T patent/PT2513093E/pt unknown
- 2010-12-13 SI SI201030770T patent/SI2513093T1/sl unknown
- 2010-12-13 PL PL10796336T patent/PL2513093T3/pl unknown
- 2010-12-13 WO PCT/EP2010/069549 patent/WO2011073154A1/en not_active Ceased
- 2010-12-13 RS RS20140526A patent/RS53555B1/sr unknown
- 2010-12-13 HR HRP20141143AT patent/HRP20141143T1/hr unknown
- 2010-12-13 EP EP16157027.0A patent/EP3091012B1/en active Active
- 2010-12-13 PL PL16157027T patent/PL3091012T3/pl unknown
- 2010-12-13 AP AP2012006276A patent/AP3170A/xx active
- 2010-12-13 ES ES16157027.0T patent/ES2674275T3/es active Active
- 2010-12-13 SG SG2012044129A patent/SG181722A1/en unknown
- 2010-12-13 MX MX2012006964A patent/MX2012006964A/es active IP Right Grant
- 2010-12-13 AU AU2010332969A patent/AU2010332969B2/en active Active
- 2010-12-13 DK DK10796336.5T patent/DK2513093T3/da active
- 2010-12-13 KR KR1020127014412A patent/KR101530234B1/ko active Active
- 2010-12-13 CA CA2782464A patent/CA2782464C/en active Active
- 2010-12-13 MY MYPI2012002736A patent/MY160471A/en unknown
- 2010-12-16 TW TW99144272A patent/TWI473800B/zh not_active IP Right Cessation
- 2010-12-16 US US12/969,745 patent/US8765949B2/en active Active
- 2010-12-16 AR ARP100104699A patent/AR079636A1/es not_active Application Discontinuation
- 2010-12-16 UY UY33109A patent/UY33109A/es not_active Application Discontinuation
2012
- 2012-04-25 IL IL219421A patent/IL219421A/en active IP Right Grant
- 2012-05-18 CL CL2012001311A patent/CL2012001311A1/es unknown
- 2012-06-13 TN TNP2012000300A patent/TN2012000300A1/en unknown
- 2012-06-14 MA MA34961A patent/MA33818B1/fr unknown
- 2012-06-15 CO CO12101565A patent/CO6650336A2/es active IP Right Grant
- 2012-06-28 EC ECSP12012010 patent/ECSP12012010A/es unknown
2014
- 2014-04-24 US US14/260,552 patent/US9670222B2/en active Active
- 2014-11-12 CY CY20141100939T patent/CY1115873T1/el unknown
2017
- 2017-05-26 US US15/606,749 patent/US10196402B2/en active Active
2018
- 2018-12-27 US US16/233,315 patent/US11046706B2/en active Active
2021
- 2021-06-11 US US17/345,110 patent/US11731981B2/en active Active
2023
- 2023-07-31 US US18/362,028 patent/US12209094B2/en active Active

Also Published As

Publication number	Publication date
US10196402B2 (en)	2019-02-05
US20170362249A1 (en)	2017-12-21
SG181722A1 (en)	2012-07-30
EP2513093B1 (en)	2014-08-27
TN2012000300A1 (en)	2013-12-12
US20240109909A1 (en)	2024-04-04
US20220002310A1 (en)	2022-01-06
BR112012015873B1 (pt)	2021-06-01
RS53555B1 (sr)	2015-02-27
MA33818B1 (fr)	2012-12-03
NZ599770A (en)	2014-06-27
AU2010332969B2 (en)	2015-02-12
GEP20146124B (en)	2014-07-25
ES2674275T3 (es)	2018-06-28
DK2513093T3 (da)	2014-09-29
ECSP12012010A (es)	2012-08-31
MX346393B (es)	2017-03-17
CL2012001311A1 (es)	2012-10-12
PT2513093E (pt)	2014-10-22
US9670222B2 (en)	2017-06-06
AR079636A1 (es)	2012-02-08
EP3091012A1 (en)	2016-11-09
CA2782464C (en)	2016-11-29
PH12012501215A1 (en)	2015-11-13
US20190300541A1 (en)	2019-10-03
EP3091012B1 (en)	2018-04-11
CN102933579B (zh)	2015-07-15
US20120004252A1 (en)	2012-01-05
EA024397B1 (ru)	2016-09-30
IL219421A0 (en)	2012-06-28
PE20121614A1 (es)	2012-12-21
BR112012015873A2 (pt)	2019-09-24
MX2012006964A (es)	2012-07-17
CN102933579A (zh)	2013-02-13
HK1178147A1 (en)	2013-09-06
EP2813503B1 (en)	2016-04-20
US11046706B2 (en)	2021-06-29
AU2010332969A1 (en)	2012-05-31
US11731981B2 (en)	2023-08-22
CO6650336A2 (es)	2013-04-15
US12209094B2 (en)	2025-01-28
EP2513093A1 (en)	2012-10-24
PL3091012T3 (pl)	2018-08-31
EA201200876A1 (ru)	2013-01-30
JP2013514301A (ja)	2013-04-25
JP5632014B2 (ja)	2014-11-26
US8765949B2 (en)	2014-07-01
MY160471A (en)	2017-03-15
ME01908B (me)	2014-12-20
PL2513093T3 (pl)	2015-03-31
EP2813503A1 (en)	2014-12-17
WO2011073154A1 (en)	2011-06-23
US20140235661A1 (en)	2014-08-21
IL219421A (en)	2015-07-30
KR101530234B1 (ko)	2015-06-19
CY1115873T1 (el)	2017-01-25
TW201130816A (en)	2011-09-16
AP2012006276A0 (en)	2012-06-30
TWI473800B (zh)	2015-02-21
PT3091012T (pt)	2018-06-27
SI2513093T1 (sl)	2014-11-28
ES2524829T3 (es)	2014-12-12
UY33109A (es)	2011-07-29
KR20120123652A (ko)	2012-11-09
CA2782464A1 (en)	2011-06-23
HRP20141143T1 (hr)	2015-01-02

Publication	Publication Date	Title
AP3170A (en)	2015-03-31	New CCR2 receptor antagonists and uses thereof
ZA201202029B (en)	2012-11-28	Androgen receptor antagonists and uses thereof
IL229507A0 (en)	2013-12-31	Extrinsic opioid receptor antagonists and their uses
ZA201203452B (en)	2014-10-29	Cgrp receptor antagonists
ZA201105323B (en)	2012-03-28	Agonists and antagonists of the sip5 receptor,and methods of uses thereof
IL212436A0 (en)	2011-06-30	Isonicotinamide orexin receptor antagonists
IL218502A0 (en)	2012-07-31	Actriib antagonists and dosing and uses thereof
PL2927224T3 (pl)	2019-03-29	Antagoniści receptora
PL2137191T3 (pl)	2016-12-30	Antagoniści obwodowego receptora opioidowego i ich zastosowania
SG10201404662YA (en)	2014-10-30	Dp2 antagonist and uses thereof
HRP20150661T1 (xx)	2015-09-25	Periferni opoidni receptor i antagonisti te njihova uporaba
IL201165A0 (en)	2010-05-17	CRIg ANTAGONISTS
ZA201105056B (en)	2012-12-27	4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
IL217526A0 (en)	2012-02-29	Carbocyclic glyt1 receptor antagonists
IL217965A0 (en)	2012-03-29	Bicyclic heterocycles and their use as ccr2 receptor antagonists
GB0701632D0 (en)	2007-03-07	MET receptor antagonists
GB0901836D0 (en)	2009-03-11	EP4 receptor antagonists
GB0900756D0 (en)	2009-03-04	EP4 Receptor antagonists
GB0900754D0 (en)	2009-03-04	EP4 Receptor antagonists
GB0900755D0 (en)	2009-03-04	Ep4 receptor antagonists
GB0705802D0 (en)	2007-05-02	Novel receptor antagonists and their methods of use
GB0709038D0 (en)	2007-06-20	Novel receptor antagonists and their methods of use